

3 November 2023

Market Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

**Results of 2023 Annual General Meeting
PolyNovo Limited**

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the proxy summary below.

Yours sincerely

Jan Gielen
CFO & Company Secretary

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
3 (a) Re-election of Robyn Elliott as Director	Ordinary	260,861,388 92.00%	19,901,101 7.02%	2,783,629 0.98%	2,391,703	272,696,355 93.22%	19,839,338 6.78%	6,841,416	Carried
3 (b) Re-election of Christine Emmanuel-Donnelly as Director	Ordinary	266,838,271 94.12%	13,897,534 4.90%	2,784,303 0.98%	2,417,713	278,673,912 95.27%	13,832,534 4.73%	6,805,663	Carried
4 Adoption of Remuneration Report	Ordinary	194,611,670 76.04%	58,257,551 22.76%	3,065,694 1.20%	2,507,872	206,192,443 77.92%	58,425,329 22.08%	7,144,014	Carried
5 Approval of Adoption/Renewal of Employee Share Option Plan	Ordinary	222,552,157 78.47%	58,229,474 20.53%	2,815,694 0.99%	1,460,496	233,856,060 78.76%	63,060,264 21.24%	1,460,496	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

For personal use only

About PolyNovo®

olyNovo is a disruptive medical device company, focused on Advanced Wound Care that designs, develops, and manufactures dermal regeneration solutions (NovoSorb BTM, NovoSorb MTX) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information see polynovo.com

About NovoSorb®

NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

Reach

PolyNovo supplies approximately 638 hospitals directly in Australia, Canada, Hong Kong, India, Ireland, the Middle East, New Zealand, Singapore, the United Kingdom, and the United States. Other countries, such as Germany, France, and Spain are serviced by a distributor.